Literature DB >> 16127084

Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.

D González de Requena1, S Bonora, S Garazzino, M Sciandra, A D'Avolio, R Raiteri, R Marrone, M Boffito, F G De Rosa, A Sinicco, G Di Perri.   

Abstract

The relationship between nevirapine plasma concentrations and the durability of both viral suppression (VS) and selection of nevirapine primary resistance mutations (PRMs) was evaluated. A nevirapine trough concentration (Ctrough) of >4,300 ng/ml was found to predict longer VS. Patients with nevirapine Ctrough s ranging from 3,100 to 4,300 ng/ml had higher probabilities of developing PRMs than those with nevirapine Ctrough s below and above this concentration interval.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127084      PMCID: PMC1195440          DOI: 10.1128/AAC.49.9.3966-3969.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Basic principles of ROC analysis.

Authors:  C E Metz
Journal:  Semin Nucl Med       Date:  1978-10       Impact factor: 4.446

Review 2.  HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors.

Authors:  Mark A Wainberg
Journal:  J Acquir Immune Defic Syndr       Date:  2003-09       Impact factor: 3.731

3.  Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography.

Authors:  G Aymard; M Legrand; N Trichereau; B Diquet
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-07-21

4.  High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.

Authors:  A I Veldkamp; G J Weverling; J M Lange; J S Montaner; P Reiss; D A Cooper; S Vella; D Hall; J H Beijnen; R M Hoetelmans
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

Review 5.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

6.  Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Authors:  N T Parkin; N S Hellmann; J M Whitcomb; L Kiss; C Chappey; C J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

  6 in total
  23 in total

Review 1.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 2.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

3.  Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.

Authors:  Andrzej Bienczak; Paolo Denti; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; Diana M Gibb; David Burger; Ann S Walker; Helen McIlleron
Journal:  AIDS       Date:  2017-04-24       Impact factor: 4.177

4.  Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.

Authors:  Retsilisitsoe R Moholisa; Michael Schomaker; Louise Kuhn; Sandra Castel; Lubbe Wiesner; Ashraf Coovadia; Renate Strehlau; Faeezah Patel; Francoise Pinillos; Elaine J Abrams; Gary Maartens; Helen McIlleron
Journal:  Pediatr Infect Dis J       Date:  2016-12       Impact factor: 2.129

5.  A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.

Authors:  Nils von Hentig; Amina Carlebach; Peter Gute; Gaby Knecht; Stefan Klauke; Maren Rohrbacher; Hartmut Stocker; Michael Kurowski; Sebastian Harder; Schlomo Staszewski; Annette Haberl
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

6.  Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.

Authors:  Andrea Calcagno; Antonio D'Avolio; Marco Simiele; Jessica Cusato; Roberto Rostagno; Valentina Libanore; Lorena Baietto; Marco Siccardi; Stefano Bonora; Giovanni Di Perri
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

7.  Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.

Authors:  Neill J Liptrott; Sudeep Pushpakom; Christoph Wyen; Gerd Fätkenheuer; Christian Hoffmann; Stefan Mauss; Heribert Knechten; Norbert H Brockmeyer; Elizabeth Hopper-Borge; Marco Siccardi; David J Back; Saye H Khoo; Munir Pirmohamed; Andrew Owen
Journal:  Pharmacogenet Genomics       Date:  2012-01       Impact factor: 2.089

Review 8.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

9.  Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.

Authors:  Monica Gandhi; Leslie Z Benet; Peter Bacchetti; Ann Kalinowski; Kathryn Anastos; Alan R Wolfe; Mary Young; Mardge Cohen; Howard Minkoff; Stephen J Gange; Ruth M Greenblatt
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-15       Impact factor: 3.731

10.  Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.

Authors:  E V Capparelli; F Aweeka; J Hitti; A Stek; C Hu; S K Burchett; B Best; E Smith; J S Read; H Watts; S Nachman; E M Thorpe; S A Spector; E Jimenez; W T Shearer; M Foca; M Mirochnick
Journal:  HIV Med       Date:  2008-04       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.